As one of the leading custom antibody generation and development providers, Creative Biolabs has launched a series of in vitro diagnostic (IVD) antibody development services targeting numerous diagnostic biomarkers of human diseases. Here, we focus on the NFKB2 as a marker of lymph cancer.
Nuclear factor NF-kappa-B p100 subunit (NFKB2)
Nuclear factor NF-kappa-B p100 subunit (NFKB2) is a protein encoded by the NFKB2 gene in humans. NF-κB has been detected in numerous cell types that express chemokines, cytokines, cell adhesion molecules, growth factors, and some acute phase proteins in health and in various disease states. NF-κB is activated by a wide variety of stimuli such as oxidant-free radicals, inhaled particles, cytokines, ultraviolet irradiation, and bacterial or viral products.
The protein NFKB2 can become mutated and lead to hereditary endocrine and immunodeficiencies. The mutation occurs at the C-terminus of NFKB2 and it causes common variable immunodeficiencies which in turn causes endocrine deficiency and immunodeficiencies. The NFKB2 mutation can cause things like adrenocorticotropic hormone deficiency and DAVID syndrome which is a pituitary hormone deficiency and CVID. The mutations that occur within the C-terminus affect the serine 866 and 870. These serines are considered phosphorylation sites for NFKB2. These mutations at the serine's in the C-terminus lead to CVID in combination with other endocrine deficiencies. These endocrine deficiencies along with the mutation of NFKB2, lead scientists to believe that mutation of NFKB2 is a rare hereditary disease called DAVID's disease.
Fig.1 Structure of the NFKB2 protein. Based on PyMOL rendering of PDB 1a3q.
NFKB2 Marker of Lymph Cancer
The Nuclear Factor Kappa B (NFkB) pathway is essential for many human cancers. NFkB is a sequence-specific transcription factor. It is crucial for the survival of B cell lymphoma. Further studies established its importance as a pro-survival factor in many cancers, not just those of lymphoid origin. NFkB is a mixed multimer of NFkB1(p50), NFKB2(p52), Rel A(p65), Rel B, and c-rel. Subunit composition, posttranscriptional modifications, and cooperating transcription factors determine target gene specificity beyond recognition of the NFkB consensus motif. Hence, mRNA profiling of NFkB responsive genes can be used to stratify malignancies, and to characterize cellular responses to natural (viral infection, growth-factor signaling) or artificial (chemotherapy drugs) stimuli.
Kaposi sarcoma (KS) is the leading cancer in people living with HIV/AIDS followed by forms of non-Hodgkin lymphoma (NHL), including Burkitt lymphoma (BL). Hodgkin lymphoma (HL) is AIDS-associated cancer that has increased in the post-HAART era. Other, so-called common cancers have also become more prevalent. These AIDS-associated lymphomas and KS are associated with gamma-herpesvirus infection. Gamma-herpesvirus infection, reactivation (and subsequent replication) is regulated by NFkB. This relationship seems almost self-evident, since gamma herpesviruses with the exception of herpesvirus saimiri, establish lifelong latency in B cells, for which NFkB is the central regulator of survival and differentiation.
IVD antibodies are extensively used in immunodiagnostic tools for disease screening and therapeutic monitoring. Through our role as a leading antibody service provider, Creative Biolabs is well-positioned to develop high-quality NFKB2-specific antibodies. Besides antibody generation, Creative Biolabs also offers diagnostic immunoassay development services, including feasibility analysis, assay design, assay protocol establishment, assay optimization, and kit production.
Creative Biolabs has successfully completed a number of IVD antibody generation and development projects for clients across the globe. If you are interested in our services, please contact us to discuss your project needs.
For Research Use Only.
